Genelux Corp
NASDAQ:GNLX

  • LAST PRICE
    2.6900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.5000/ 2
  • Ask / Lots
    2.9000/ 3
  • Open / Previous Close
    2.7200 / 2.6900
  • Day Range
    2.6400
    2.7200
  • 52 Week Range
    1.6000
    16.6000
  • Volume
    47,784

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 15, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 4:07PM ET on Thursday Nov 14, 2024 by MT Newswires
      Companies Mentioned: GNLX
      04:07 PM EST, 11/14/2024 (MT Newswires) -- ...

    • 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: GNLX
      34,538,185 and 26,788,986 shares issued and outstanding 35 27 Treasury stock, 433,333 shares, at cost (433) (433) Additional paid-in capital 275,782 241,389 Accumulated other comprehensive income 124 14 Accumulated deficit (242,417) (221,524) ---------- --------- Total Shareholders' Equity 33,091 19,473 ---------- --------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 40,270 $ 27,893 ========== ========= The accompanying notes are an integral part of these condensed financial statements. Genelux Corporation Condensed Statements of Operations (in thousands, except for share amounts and per share data) Three Months Ended Nine Months Ended September 30, September 30, -------------------------- ---------------------------- 2024 2023 2024 2023 (Unaudited) (Unaudited) Revenues $ - $ - $ 8 $ 170 ---------- ---------- ---------- ---------- Operating expenses: Research and development 4,051 2,819 12,478 8,607 General and administrative 2,890 2,488 9,478 8,727 ---------- ---------- ---------- ---------- Total operating expenses 6,941 5,307 21,956 17,334 ---------- ---------- ---------- ---------- Loss from operations (6,941) (5,307) (21,948) (17,164) ---------- ---------- ---------- ---------- Other income (expenses): Interest income 474 4 1,055 4 Interest expense - - - (167) Debt discount amortization - - - (649) Financing costs - (42) - (3,152) Debt extinguishment costs - (402) Total other income (expenses), net 474 (38) 1,055 (4,366) ---------- ---------- ---------- ---------- NET LOSS $ (6,467) $ (5,345) $ (20,893) $ (21,530) ========== ========== ========== ========== LOSS PER COMMON SHARE - BASIC AND DILUTED $ (0.19) $ (0.20) $ (0.69) $ (0.91) ========== ========== ========== ========== WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC AND DILUTED 34,532,355 26,210,068 30,405,615 23,640,995 ========== ========== ========== ========== The accompanying notes are an integral part of these condensed financial statements. Genelux Corporation Condensed Statements of Comprehensive Loss (in thousands) Three Months Ended Nine Months Ended September 30, September 30, ------------------ ---------------------- 2024 2023 2024 2023 (Unaudited) (Unaudited) Net loss $(6,467) $(5,345) $(20,893) $(21,530) Other comprehensive loss: Net unrealized gain on short and long-term investments 135 - 110 - Comprehensive loss $(6,332) $(5,345) $(20,783) $(21,530) ====== ====== ======= ======= The accompanying notes are an integral part of these condensed financial statements.

    • 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: GNLX
      34,538,185 and 26,788,986 shares issued and outstanding 35 27 Treasury stock, 433,333 shares, at cost (433) (433) Additional paid-in capital 275,782 241,389 Accumulated other comprehensive income 124 14 Accumulated deficit (242,417) (221,524) ---------- --------- Total Shareholders' Equity 33,091 19,473 ---------- --------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 40,270 $ 27,893 ========== ========= The accompanying notes are an integral part of these condensed financial statements. Genelux Corporation Condensed Statements of Operations (in thousands, except for share amounts and per share data) Three Months Ended Nine Months Ended September 30, September 30, -------------------------- ---------------------------- 2024 2023 2024 2023 (Unaudited) (Unaudited) Revenues $ - $ - $ 8 $ 170 ---------- ---------- ---------- ---------- Operating expenses: Research and development 4,051 2,819 12,478 8,607 General and administrative 2,890 2,488 9,478 8,727 ---------- ---------- ---------- ---------- Total operating expenses 6,941 5,307 21,956 17,334 ---------- ---------- ---------- ---------- Loss from operations (6,941) (5,307) (21,948) (17,164) ---------- ---------- ---------- ---------- Other income (expenses): Interest income 474 4 1,055 4 Interest expense - - - (167) Debt discount amortization - - - (649) Financing costs - (42) - (3,152) Debt extinguishment costs - (402) Total other income (expenses), net 474 (38) 1,055 (4,366) ---------- ---------- ---------- ---------- NET LOSS $ (6,467) $ (5,345) $ (20,893) $ (21,530) ========== ========== ========== ========== LOSS PER COMMON SHARE - BASIC AND DILUTED $ (0.19) $ (0.20) $ (0.69) $ (0.91) ========== ========== ========== ========== WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC AND DILUTED 34,532,355 26,210,068 30,405,615 23,640,995 ========== ========== ========== ========== The accompanying notes are an integral part of these condensed financial statements. Genelux Corporation Condensed Statements of Comprehensive Loss (in thousands) Three Months Ended Nine Months Ended September 30, September 30, ------------------ ---------------------- 2024 2023 2024 2023 (Unaudited) (Unaudited) Net loss $(6,467) $(5,345) $(20,893) $(21,530) Other comprehensive loss: Net unrealized gain on short and long-term investments 135 - 110 - Comprehensive loss $(6,332) $(5,345) $(20,783) $(21,530) ====== ====== ======= ======= The accompanying notes are an integral part of these condensed financial statements.

  • Nov 6, 2024

Peers Headlines